RxDoctor Payments Data

Raetta Fountain, MD

Gastroenterology · Greenville, NCNPI 1487643854

Payments from drug & device makers

$52,087in general payments, 2019–2025

Across 717 payments — averaging $72.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$43K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$704
  • Johnson & Johnson$654
  • Pfizer$498
  • Gilead$455
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$12,630100%
  • Education$240%
  • Gifts$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,087 in reported general payments places this provider in the 85th percentile of 610 gastroenterology providers in North Carolina.

See all gastroenterology providers in North Carolina

Medicare billing

Part B allowed, 2024
$209,833
Medicare patients
477
Services billed
9,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab43$1,186,098
SucraidSacrosidase15$264,092
Humira(Cf) PenAdalimumab13$162,820
CreonLipase/Protease/Amylase59$158,557
ZenpepLipase/Protease/Amylase40$143,257
RemicadeInfliximab13$143,022
LinzessLinaclotide78$75,507
XifaxanRifaximin22$66,470
IbsrelaTenapanor Hcl25$47,102
ViberziEluxadoline18$18,032
Dexlansoprazole DrDexlansoprazole47$16,172
TrulancePlecanatide21$15,109
VoqueznaVonoprazan Fumarate19$13,925
Mesalamine24$7,401
MovantikNaloxegol Oxalate17$6,733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Remicade$654$1,329,12056 claims
QOL Medical, LLCSucraid$450$264,09215 claims
AbbVieCreon, Linzess, Viberzi$42,571$252,096155 claims
Aimmune Therapeutics, Inc.Zenpep$341$143,25740 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,482$81,57943 claims
Ardelyx, Inc.Ibsrela$213$47,10225 claims
Phathom Pharmaceuticals, Inc.Voquezna$112$13,92519 claims
Redhill Biopharma Inc.Movantik$97$6,73317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 610 gastroenterology providers in North Carolina.

Other gastroenterology in Greenville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →